Internal Reference Number: FOI_9029
Date Request Received: 11/11/2025 00:00:00
Date Request Replied To: 17/11/2025 00:00:00
This response was sent via: By Email
Request Summary: Endometrial Cancer
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of endometrial cancer. I would greatly appreciate if you could answer the following questions. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: • Dostarlimab (Jemperli) • Dostarlimab (Jemperli) AND Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Pembrolizumab (Keytruda) monotherapy • Lenvatinib + Pembrolizumab (Lenvima +Keytruda)  • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other Chemotherapy • Durvalumab with platinum-based chemotherapy • Pembrolizumab with platinum-based chemotherapy | |
| Answer To Question 1: • Dostarlimab (Jemperli) 0 • Dostarlimab (Jemperli) AND Chemotherapy <5 • Hormone therapy (Progesterone or Letrozole) unable to answer as not on chemo eprescribing system • Pembrolizumab (Keytruda) monotherapy 0 • Lenvatinib + Pembrolizumab (Lenvima +Keytruda) <5 • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) <5 • Any other SACT 0 • Any other Chemotherapy 0 • Durvalumab with platinum-based chemotherapy 0 • Pembrolizumab with platinum-based chemotherapy <5 | |
| Question Number 2: In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy? | |
| Answer To Question 2: <5 | |
| Question Number 3: Q3. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: • Dostarlimab (Jemperli) AND Chemotherapy • Durvalumab with platinum-based chemotherapy • Pembrolizumab with platinum-based chemotherapy • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other chemotherapy | |
| Answer To Question 3: • Dostarlimab (Jemperli) AND Chemotherapy <5 • Durvalumab with platinum-based chemotherapy 0 • Pembrolizumab with platinum-based chemotherapy <5 • Hormone therapy (Progesterone or Letrozole) - unable to answer as not on chemo eprescribing system • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) <5 • Any other SACT 0 • Any other chemotherapy0 | |
| Question Number 4: Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 4: 0 in 2025 | |
| To return to the list of all the FOI requests please click here |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
